The enormous volume of literature describing the aberrant expression of CEACAM5 and CEACAM6 in various types of cancers, the prognostic values of such expression, and CEACAM5-targeted therapies has tended to dilute studies revealing the significant biologic functions of these antigens and their potential clinical implications. The gene discussed is CEACAM5; the disease is cancer.